Terumo and UMCU Strengthen their Partnership to Develop Solutions in Interventional Oncology

Terumo Europe and University Medical Center Utrecht (UMC Utrecht) announced today that they signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology. In the past years, both parties have successfully collaborated in technology transfer, product development and the advancement of clinical evidence in the field of Selective internal radiation therapy, referred to as SIRT (also known as Radioembolization, RA or Transarterial radioembolization, TARE) for the treatment of unresectable liver tumors.

The MoU marks the continuation of the existing partnership and confirms the shared interest of both parties to enhance education and innovations to develop meaningful solutions that provide significant clinical benefits to patients with cancer and increase their access to treatments.

Quirem Medical, a wholly owned subsidiary of Terumo since July 2020,  based in Deventer, originated as a spin-off from the UMC Utrecht in 2013. Quirem Medical manufactures QuiremSpheres™, the only commercially available microspheres containing the radioactive isotope Holmium-166. Trials have shown the safety and efficacy of holmium microspheres in the treatment of unresectable liver tumors. Quirem Medical also manufactures the SIRT work-up product QuiremScout™ Holmium-166 Microspheres, which is used prior to the therapy to select patients and plan the SIRT procedure. Across Europe, hundreds of patients are treated with QuiremSpheres™ Holmium-166 Microspheres and QuiremScout™ Holmium-166 Microspheres every year.

With the acquisition of Quirem Medical in 2020 and the creation of the Global TIO team in 2021, we see great opportunities to leverage the broad Terumo technology base in interventional oncology for improved cancer care. The UMC Utrecht has proven a highly reliable, professional & innovative clinical partner with a strong focus on image guided therapies in cancer care. As such, the UMC Utrecht is a partner of choice in this journey; and we look forward to a successful continuation of our close collaboration in education, innovation and data generation to contribute to society through healthcare together.” Says Ghada Farah, Senior Vice President Terumo Interventional Systems EMEA.

Terumo, a global leader in medical technology, announced on April 12, 2021 the launch of its Global Therapeutic Interventional Oncology (TIO) team. This reflects Terumo’s aspiration to be a global leader in the field of Interventional Oncology by focusing on improving patient’s quality of life and survival.

“Terumo and the UMC Utrecht have a fruitful history of collaboration on QuiremSpheres™ Holmium-166 Microspheres for radioembolization of liver tumors. This Memorandum of Understanding underlines the collaboration that is already there for QuiremSpheres™ Holmium-166 Microspheres and the ambition to collaborate in the broader range of interventional oncology, including tumor ablation and chemoembolization. Terumo’s dedication to improve patient care and the company’s global reach make Terumo an ideal partner for this journey.” says Dr. Maarten Smits, Interventional Radiologist, UMC Utrecht

SourceTerumo
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version